RCS - OptiBiotix Health - Company update on activities

OptiBiotix HealthAnnouncement

29/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240729:nRSc0807Ya&default-theme=true

RNS Number : 0807Y  OptiBiotix Health PLC  29 July 2024

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

29 July 2024

Company update on activities

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, cardiovascular disease, diabetes and skincare,
provides an update on Company activities and current outlook.

 

OptiBiotix's products have been developed to meet the needs of global
megatrends.  Given the long development timeline for new products with
clinical studies and the difficulties of predicting future trends, OptiBiotix
developed a broad portfolio of products to mitigate risks.  However, a number
of recent market reports suggest that products across all of OptiBiotix's
portfolio have potential to meet growing market trends as highlighted in the
links below:-

 

a.    Proven Scientific and clinically efficacy is a key consumer
requirement in purchasing health products The top wellness trends in 2024 |
McKinsey
(https://urldefense.proofpoint.com/v2/url?u=https-3A__www.mckinsey.com_industries_consumer-2Dpackaged-2Dgoods_our-2Dinsights_the-2Dtrends-2Ddefining-2Dthe-2D1-2Dpoint-2D8-2Dtrillion-2Ddollar-2Dglobal-2Dwellness-2Dmarket-2Din-2D2024&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=qE1yMNvX8OUmO7FV4SLAuFx81K4O8nrPcCbRUEpXKXA&m=x0OrsmcGfE8jAd14hj-cz8eye9XcK05jc6O4fCP_mOrGHEhlJ3RXq9BMEujA4xUq&s=FC_TXaVnZkV8g8I907MpAl7i6P5khyhVLkSIrVYhT6g&e=)

b.    Natural weight management/appetite suppressants like SlimBiome®
https://www.verifiedmarketreports.com/product/appetite-suppressants-market/
(https://www.verifiedmarketreports.com/product/appetite-suppressants-market/)

c.     Digestive Health and the Microbiome (WellBiome®, Microbiome
modulators) - Ten Key Health and Nutrition Trends for 2024 - KHNI (kerry.com)
(https://urldefense.proofpoint.com/v2/url?u=https-3A__khni.kerry.com_trends-2Dand-2Dinsights_ten-2Dkey-2Dhealth-2Dand-2Dnutrition-2Dtrends-2Dof-2Dthis-2Dyear_&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=qE1yMNvX8OUmO7FV4SLAuFx81K4O8nrPcCbRUEpXKXA&m=x0OrsmcGfE8jAd14hj-cz8eye9XcK05jc6O4fCP_mOrGHEhlJ3RXq9BMEujA4xUq&s=A0M8oxdbSnuWU4HGewB_s8L4UoaqgBulULboMaRzevo&e=)

d.    Sugar reduction (SweetBiotix® Ten Key Health and Nutrition Trends
for 2024 - KHNI (kerry.com)
(https://urldefense.proofpoint.com/v2/url?u=https-3A__khni.kerry.com_trends-2Dand-2Dinsights_ten-2Dkey-2Dhealth-2Dand-2Dnutrition-2Dtrends-2Dof-2Dthis-2Dyear_&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=qE1yMNvX8OUmO7FV4SLAuFx81K4O8nrPcCbRUEpXKXA&m=x0OrsmcGfE8jAd14hj-cz8eye9XcK05jc6O4fCP_mOrGHEhlJ3RXq9BMEujA4xUq&s=A0M8oxdbSnuWU4HGewB_s8L4UoaqgBulULboMaRzevo&e=)

 

The recent article in the Daily Mail MIDAS column, available here
(https://www.thisismoney.co.uk/money/investing/article-13615305/Investors-Ozempic-huge-profits-stock-picking-expert-unearths-companies-working-blockbuster-treatments-future-make-packet.html)
, highlights the potential for SlimBiome® as a natural alternative to the
blockbuster weight loss drugs that are currently on the market and how the
launch of these drugs has increased interest in natural products like
SlimBiome® which help users lose weight by suppressing their appetite.
Media interest has helped OptiBiotix secure a number of interviews with
journalists and an article in the August issue of Nutrition Industry Executive
(NIE), a publication widely read by industry decision-makers in the USA.

 

OptiBiotix has been raising awareness of the potential for its clinically
proven product, SlimBiome®, which works in a similar way to Ozempic/Wegovy to
reduce hunger and cravings to support weight loss in overweight
individuals. OptiBiotix's commercial focus has been on overweight
individuals, but recent work with dieticians at a speciality London obesity
clinic has indicated SlimBiome® may have potential as an adjunct to treatment
with Ozempic/Wegovy.

 

Reports suggest that patients taking anti-obesity drugs often have a
decreasing effect over time despite increasing dose. To counter this, a small
number of patients were given SlimBiome® with patients reporting an enhanced
appetite suppressant effect. Work is ongoing to explore whether SlimBiome®
combined with Ozempic may help to reduce drug dosage (and cost), enhance, or
prolong the appetite suppressant effect of these anti -obesity drugs.

 

In line with its strategy of selling more final product and expanding its
interests in the USA, the Company is pleased to announce it has received its
first order from a NASDAQ listed USA ecommerce and direct selling company.
This is for a tomato soup final product which is expected to be launched in
January 2025. This is one of a number of US companies the Company has been
working with on SlimBiome®, WellBiome®, SweetBiotix®, and its microbiome
modulators.

 

Stephen O'Hara, CEO of OptiBiotix Health plc said: "We have made real progress
this year in progressing our commercialisation strategy of building sales in
major international markets like the USA, China, and India, building our
ecommerce channels, and selling more final product. We are pleased to report
that in just one day this month (July), we achieved our highest daily sales of
SlimBiome® on Amazon UK and our own ecommerce site of over £2,400; with
SlimBiome® achieving the No.1 best seller for appetite suppressants on
Amazon. We're excited about the potential of  SlimBiome® as a natural
alternative or potential adjunct to anti -obesity drugs and are working to
increase awareness of the potential opportunities this brings to investors and
consumers."

 

 

For further information, please contact:

 

 OptiBiotix Health plc                        www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Peterhouse Capital Limited (Broker)          Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                              Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

 

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZQLFLZDLFBBZ